Drug Trial Radar · NCT07114861
The KN510713 Study in Combination With mFOLFIRINOX
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Dec 16, 2025
Primary completion
Sep 22, 2028
Study completion Oct 22, 2028
Sponsor
- Lead sponsor
- New Cancer Cure-Bio Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety and efficacy of KN510713 in combination with mFOLFIRINOX in patients with locally advanced or metastatic pancreatic cancer. The study will be conducted in two parts: Part 1 (Dose-finding) and Part 2 (Dose expansion).
Conditions
- Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Study drug: KN510 120mg/day + KN713 90mg/day, Combination Chemotherapy: mFOLFIRINOXDrug
KN510 120mg/day + KN713 90mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks
Study drug: KN510 120mg/day + KN713 120mg/day, Combination Chemotherapy: mFOLFIRINOXDrug
KN510 120mg/day + KN713 120mg/day: once daily in 14-day (2-week) cycles. mFOLFIRINOX: Treatment is repeated every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of occurrences, affected subjects with adverse events.Time frame: Through study completion, an average of 12 months
- The frequency and percentage of Dose-Limiting ToxicitysTime frame: 4 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cancer Center
Goyang-si, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.